Consistently, HDAC inhibitors (vorinostat and curcumin), especially dual HDAC and cancer‐promoting pathway inhibitors (CUDC‐901 and CUDC‐907), exhibited growth‐inhibitory effects across different GBC organoids with low toxicity to normal gallbladder organoids, suggesting a safe and effective treatment regimen in GBC. Here, HDAC9 is linked to cancer.